VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.
SAN DIMAS, Calif., Jan. 20 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a suit in Delaware federal court against Liposome Technology, Inc. Vestar's complaint asks the court to declare that a patent obtained yesterday by Liposome Technology is invalid and is not infringed by Vestar's product, AmBisome(R). Yesterday, Vestar commented that the methodology described in the Liposome Technology patent appeared not to be relevant to AmBisome. Liposome Technology's patent concerns a process for preventing the alteration in size of liposomes that enclose amphotericin B. It also describes increased toxicity when such size changes occur. Vestar stated that since AmBisome does not change size before freeze drying or after reconstitution back to a liquid solution, Vestar does not need any process to prevent size changes. Vestar further noted that the company believes the size of stability of AmBisome is one of the reasons that the toxicity of AmBisome is so low. Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. Since 1989, Vestar has been marketing in Europe AmBisome, a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is in development as Vestar's second major product. -0- 1/20/93 /CONTACT: Michael E. Hart, chief financial officer of Vestar, Inc., 714-394-4119 or Marcia A. Kean, executive VP of Feinstein Partners Inc., 617-577-8110/ (VSTR)
CO: Vestar ST: California IN: MTC SU:
SJ-TM -- NE002 -- 6703 01/20/93 07:59 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 20, 1993|
|Previous Article:||NORWEST CORPORATION REPORTS RECORD ANNUAL AND QUARTERLY EARNINGS|
|Next Article:||INDEPENDENCE REPORTS NET INCOME OF $11.5 MILLION FOR 1992; DIVIDEND DECLARED|